Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2013

01-06-2013 | Melanomas

How Often do Level III Nodes Bear Melanoma Metastases and does it Affect Patient Outcomes?

Authors: Carolyn Nessim, MD, Calvin Law, MD, Yarrow McConnell, MD, Sade Shachar, MD, Gregory McKinnon, MD, Frances Wright, MD

Published in: Annals of Surgical Oncology | Issue 6/2013

Login to get access

Abstract

Background

Limited data exist regarding the necessity of resecting level three nodes as part of an axillary dissection for melanoma. The objective of this study was to determine how often level III nodes have metastases, in patients with sentinel lymph node (SLN) positive, palpable and bulky axillary disease, and to determine patient outcomes.

Methods

A retrospective chart review was completed at two tertiary care centers of patients with melanoma that had level three axillary dissections. At the time of surgery, the level III nodes were sent as a separate specimen. Bulky disease was defined as a large mass in all three levels that could not be separated.

Results

A total of 117 patients were identified. Three percent and 18 % of patients with SLN+ and palpable disease, respectively, had further disease in their level III nodes. All bulky patients had level III disease. Those with level III disease had a worse 3-year overall survival than those who did not (15.2 vs. 61.1 %, p < 0.001). For patients with palpable and bulky disease, systemic recurrence rate was 65 and 88 %, with a median time to metastases of 13.6 and 2 months, respectively.

Conclusions

Patients with SLN+ disease rarely have positive level III nodes, questioning the need for routine removal of these nodes. Patients with palpable and bulky lymph node disease have implied occult distant metastases at the time of diagnosis and treatment. With the advent of improved targeted therapies for melanoma, clinical trials evaluating their role in patients with stage III disease may be warranted to improve patient outcomes.
Literature
1.
Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3622–34.PubMed
2.
Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma: prognostic variables in node-positive patients. Ann Surg. 1990; 212:125–31.PubMedCrossRef
3.
Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.PubMedCrossRef
4.
Wright F, Spithoff K, Easson A, Murray C, Toye J, McCready D, Patrella T. Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk and extremities. Clin Oncol. 2011;23:572–8.CrossRef
5.
Plitas G, Aryian CE. Controversies in the management of regional nodes in melanoma. J NCCN. 2012;10:414–21.
6.
Mack LA, McKinnon G. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189–99.PubMedCrossRef
7.
Ariyan C, Brady MS, Gönen M, Busam K, Coit D. Positive non-sentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16:186–90.PubMedCrossRef
8.
Ghaferi AA, Wong SL, Johnson TM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol. 2009;16:2978–84.PubMedCrossRef
9.
Easson AM, Rotstein LE, McCready DR. Lymph node assessment in melanoma. J Surg Oncol. 2009;99:176–85.PubMedCrossRef
10.
Karakousis CP. Therapeutic Node Dissections in Malignant Melanoma. Ann Surg Oncol. 1998;5:473–82.PubMedCrossRef
11.
Meyer T, Merkel S, Göhl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. EJSO. 2002; 28:424–30.PubMedCrossRef
12.
van Akkooi ACJ, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. EJSO. 2007;33:102–8.PubMedCrossRef
13.
Young SE, Martinez SR, Faries MB, Essner R, Wanek LA, Morton DL. Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer J. 2006;12:207–11.PubMedCrossRef
14.
Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg. 2003;10:676–80.CrossRef
15.
Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level II and level III node dissection in addition to mastectomy for breast cancer. Br J Surg. 2004;91:38–43.PubMedCrossRef
16.
Larson D, Weinstein M, Goldberg I et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I–II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575–82.PubMedCrossRef
17.
Pezner RD, Patterson MR, Hill LR et al. Arm Lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys. 1986;12:2079–83.PubMedCrossRef
18.
19.
20.
Namm JP, Chang AE, Cimmino VM, Rees RS, Johnson TM, Sabel MS. Is a level III dissection necessary for a positive sentinel lymph node in melanoma? J Surg Oncol. 2012;105:225–8.PubMedCrossRef
21.
Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol. 2009;27:544–57.
22.
Saha S, Farrar WB, Young DC, Ferrara JJ, Burak WE. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol. 2000;73:134–7.PubMedCrossRef
23.
Valsecchi ME, Silbermins D, deRosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29:1479–87.PubMedCrossRef
24.
Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104:341–53.PubMed
25.
Cadili A, McKinnon G, Wright F, Hanna W, Macintosh E, Abhari Z, Dabbs K. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. J Surg Oncol. 2010;101:191–4.PubMed
26.
Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–59.PubMedCrossRef
27.
Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051–55.PubMedCrossRef
28.
Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. 1981;193:377–88.PubMedCrossRef
29.
30.
Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3-7.PubMedCrossRef
31.
Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncol. 2011;5:124–36.CrossRef
32.
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRef
33.
Gajewski TF. Molecular Profiling of melanoma and the evolution of patient-specific therapy. Sem Oncol. 2011;38:236–42.CrossRef
34.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711.PubMedCrossRef
35.
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517.PubMedCrossRef
Metadata
Title
How Often do Level III Nodes Bear Melanoma Metastases and does it Affect Patient Outcomes?
Authors
Carolyn Nessim, MD
Calvin Law, MD
Yarrow McConnell, MD
Sade Shachar, MD
Gregory McKinnon, MD
Frances Wright, MD
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2880-2

Other articles of this Issue 6/2013

Annals of Surgical Oncology 6/2013 Go to the issue

Thoracic Oncology

Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal Downstaging After Induction Chemotherapy and Surgery

Urologic Oncology

Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy

Gastrointestinal Oncology

Neoadjuvant Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer in a Single High-Volume Center

Hepatobiliary Tumors

Role of Major Vascular Resection in Patients with Intrahepatic Cholangiocarcinoma

Breast Oncology

Variation in the Utilization of Reconstruction Following Mastectomy in Elderly Women

Healthcare Policy and Outcomes

Comprehensive Databases: A Cautionary Note